[PHHI (persistent hyperinsulinemic hypoglycemia of infancy)].
Nagashima
Kazuaki
K
Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
D018528:ATP-Binding Cassette Transporters; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003981:Diazoxide / Q000627:therapeutic use; D006801:Humans; D006946:Hyperinsulinism / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D007003:Hypoglycemia / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D007223:Infant; D007231:Infant, Newborn; D009154:Mutation; D009543:Nifedipine / Q000627:therapeutic use; D010180:Pancreatectomy; D015221:Potassium Channels / Q000235:genetics; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics; D011379:Prognosis; D011955:Receptors, Drug; D064233:Sulfonylurea Receptors
D018528:ATP-Binding Cassette Transporters; D002121:Calcium Channel Blockers; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug; D064233:Sulfonylurea Receptors; D009543:Nifedipine; D003981:Diazoxide